Current Status and Future Perspectives of Immunotherapies in Bladder Cancer by Gökhan Çolak, Bilgin Demir

Get full text

Second-line Chemotherapy for Advanced Bladder Cancer: Taxanes Versus Vinflunine by Bilgin Demir, Ali Aytaç, Gökhan Çolak, Onur Yazdan Balçık, Ömer Acar

Get full text

Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study by Mehmet Nuri Baser, Bilgin Demir, Gamze Serin Ozel, Gamze Gokoz Dogu, Serdar Karakaya, Mucahit Ugar, Naziye Ak, Ahmet Ozveren, Ufuk Camanlı, Olcun Umit Unal, Merve Turan, Esin Oktay

Get full text

Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study by Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık, Mustafa Şahbazlar, Mehmet Türker, Oğuzcan Kınıkoğlu, Tahir Yerlikaya, Gülhan Dinç, Ali Aytaç, Ziya Kalkan, Senar Ebinç, İlkay Gültürk, Merve Keskinkılıç, Zehra Sucuoğlu İşleyen, Dilek Çağlayan, Alper Türkel, Esra Aydın, Teoman Şakalar, Serhat Sekmek, Nilgün Yıldırım, Sinem Koçak, Kerem Okutur, Ahmet Özveren, Bengü Dursun, Sait Kitaplı, Orhan Önder Eren, İsmail Beypınar, İlhan Hacıbekiroğlu, Devrim Çabuk, Elanur Karaman, Ömer Acar, Semra Paydaş, Melek Karakurt Eryılmaz, Bilgin Demir, Zeynep Oruç, Mesut Yılmaz, Fatih Selçuk Biricik, Derya Kıvrak Salim, Özgür Tanrıverdi, Mutlu Doğan

Get full text